Drug | Type and target | Disease, stage and references |
---|---|---|
Avastin/Bevacizumab | mAb against VEGF75 | Multiple tumour types including: CRC, NSCLC, and breast cancer (FDA app) |
Pazopanib/ GW786034 | TKI of VEGFR-1,-2,-3, PDGFRα,-β, Kit, FGFR-1,-3, Itk, Lek, c-Fms76 | Multiple tumour types including: solid tumours (with paclitaxel/carboplatin, Phase I), RCC (FDA app)77 |
Imatinib/STI157 | TKI of PDGFRβ ,Bcr-Abl, Kit78 | Multiple tumour types including: GIST (FDA app)78 |
Sunitinib/SU11248 | TKI of VEGFR1-,2,-3, PDGFRα,-β, Kit, FLT-3, CSF1R, RET78 | GIST (imatinib resist; FDA app), RCC (FDA app), NSCLC (Phase III)78 79 |
Motesanib | TKI of VEGFR1,-2, PDGFRβ, Kit, RET80 | NSCLC (with carboplatin/paclitaxel, Phase III), breast cancer (with docetaxel/paclitaxel, Phase I/II)80–82 |
Sorafenib | TKI of VEGFR2,-3, PDGFRβ Kit, RET, B-Raf, FLT-378 83 | Multiple tumour types including: RCC (FDA app), HCC (FDA app)83 |
CSF1R, colony-stimulating factor 1 receptor; CRC, colorectal carcinoma; FDA app, Food and Drug Administration approved; FLT-3, FMS-like tyrosine kinase-3; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; Itk, interleukin-2 receptor inducible T-cell kinase; Lek, leucocyte-specific protein tyrosine kinase; NSCLC, non-small cell lung cancer; PDGFR/PDGFR-α/β, platelet-derived growth factor receptor-α/β; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; mAb, monoclonal antibody; TKI, tyrosine kinase inhibitors; FGFR, fibroblast growth factor receptor; RET, rearranged during transfection.